Compare American Express Co (AXP) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Express Co vs BioNano Genomics Inc — how do they compare? American Express Co trades at $343.84 (market cap $230.15B), while BioNano Genomics Inc trades at $1.18 (market cap $13.66M). The key difference: American Express Co is far larger — about 16848.5× BioNano Genomics Inc's market cap, and American Express Co pays a 1.11% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| AXP | BNGO | |
|---|---|---|
Market Cap | $230.15B | $13.66M |
Sector | Financials | Health |
52-Week High | $384.82 | $4.92 |
52-Week Low | $292.27 | $1.06 |
Dividend Yield | 1.11% | — |
Enterprise Value | — | $16.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXP trades at $343.22, up 1.29% today, with a bullish technical signal and strong support at $339. The stock shows robust fundamentals with 2025 revenue of $72.23B and net income of $10.83B, though recent earnings have been mixed. Analyst consensus is a $369.42 price target with 40% buy ratings. Recent news highlights Amex Ventures' AI investments and premium cardmember benefits, reinforcing growth initiatives.
Outlook remains positive due to steady revenue growth and high ROE of 33.97%, but risks include competitive pressures and a P/E of 20.68 above sector averages. The stock offers upside to consensus targets if execution continues, though investors should monitor spending trends and economic sensitivity.
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Express Co
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
